D-chiro-Inositol (commonly abbreviated DCI) is a member of a family of related substances often referred to collectively as “inositol,” although that term encompasses several isomers of questionable biological relevance. It is known to be an important secondary messenger in insulin signal transduction.
Source: Wikipedia
We evaluated the effects of a therapy that combines myo-inositol (MI) and D-chiro-inositol (DCI) in young overweight women affected by polycystic ovary syndrome (PCOS), characterized by oligo- or anovulation and hyperandrogenism, correlated to insulin resistance.
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome, involving a growing number of women in reproductive age, diagnosed on the basis of three different factors: oligo- or anovulation, clinical/biochemical hyperandrogenism, and polycystic ovary, with the presence on ultrasound of ≥12 follicles in each ovary measuring mm in diameter and/or increased ovarian volume (>10 mL)
Interesting and promising results have been obtained focusing on two inositol stereoisomers, such as myo-inositol (MI) and D-chiro-inositol (DCI), acting like insulin mediators. As insulin second messengers, both these molecules are involved in increasing insulin sensitivity of different tissues to improve metabolic and ovulatory functions.
The combined therapy of MI plus DCI is effective in improving endocrine and metabolic parameters in young obese PCOS affected women.
D-chiro-Inositol
Chromatogram(s) using Benson Polymeric Columns
Part No.:
Eluent:
Flow Rate:
Detection:
Temperature:
Sample Size:
Column Size:
Resin Type:
DI H2O
0.8 ml/min
RI
85 C
20 ul, 30 mg/ml
300 x 7.8 mm
8% Pb
2 – chiro-Inositol
3 – myo-Inositol
Part No.:
Eluent:
Flow Rate:
Detection:
Temperature:
Sample Size:
Column Size:
Resin Type:
DI H2O
0.8 ml/min
RI
85 C
20 ul, 30 mg/ml
300 x 7.8 + 100 x 7.8 mm
8% Pb
2 – chiro-Inositol
3 – myo-Inositol
You must be logged in to post a comment.